Irinotecanhydrochlorid 3 H2o Phares

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecanhydrochlorid 3 H2O Phares, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It treats metastatic colorectal cancer and selected advanced solid tumors, typically in combination with other chemotherapy agents.

GNH USA supplies Irinotecanhydrochlorid 3 H2O Phares as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Irinotecan is a topoisomerase I inhibitor used in chemotherapy regimens for gastrointestinal and other solid tumors.

- Metastatic colorectal cancer: improves progression‑free survival when combined with fluoropyrimidine‑based regimens. - Advanced small cell lung cancer: contributes to tumor response as part of multi‑agent therapy. - Gastric cancer: used in combination protocols to enhance antitumor activity in unresectable disease.

Irinotecan may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy. - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: gastrointestinal upset commonly reported. - Alopecia: hair loss may occur during treatment.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent medical care. - Severe colitis: inflammation of the colon that can be life‑threatening. - Hypersensitivity reactions: rash, bronchospasm or anaphylaxis. - Hepatotoxicity: elevated liver enzymes indicating liver injury.

When using irinotecan, clinicians should observe several safety measures to minimize risks.

- Baseline blood counts: obtain complete blood count before each cycle to monitor neutropenia. - Liver function: assess hepatic enzymes as impaired metabolism can increase toxicity. - Diarrhea prophylaxis: initiate antidiarrheal agents and educate patients on early signs. - Drug interactions: review concomitant medications that affect CYP3A4 or UGT1A1. - Pregnancy and lactation: avoid use; safety not established. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan interacts with several medicines that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce SN‑38 formation and therapeutic effect. - UGT1A1 inhibitors (e.g., atazanavir, indinavir): can increase SN‑38 exposure, raising risk of severe neutropenia and diarrhea. - Concurrent use with other myelosuppressive agents: may potentiate bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may exacerbate constipation and ileus. - Anticoagulants (warfarin, DOACs): monitor for bleeding as irinotecan can affect platelet function. - Proton pump inhibitors: may modestly affect gastric pH and absorption of oral formulations.